STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1613 by analyst upside · 2026-08-13
EVH
Evolent Health, Inc.
Healthcare · Market Cap $471M · P/E 0x
ANALYST PRICE TARGET
+36.5%
implied upside to consensus target
Current Price $4.17
Consensus Target $5.69
Bull Target $8.0
Bear Target $3.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
7
Hold
3
Sell
0
52-Week Low $2.1
52-Week High $10.08
YTD Return +7.2%
FUNDAMENTALS
Market Cap $471M
P/E Ratio (TTM) N/A
Forward P/E 10.8x
EPS (TTM) $-4.57
PEG Ratio 1.93
Dividend Yield N/A
Revenue (TTM) $2.1B
Profit Margin -24.1%
52-WEEK RANGE
52-Week Low $2.1
52-Week High $10.08
Current Price $4.17
Bear Target $3.0
Bull Target $8.0
● Now $4.17 ● Target $5.69
TRADING DATA
Avg Volume 3.0M
YTD Return +7.2%
Analyst Count 13
Consensus Buy
Upside to Target +36.5%
Last Updated 2026-08-13

ANALYST SUMMARY

Evolent Health, Inc. (EVH) is currently trading at $4.17 with a Wall Street consensus price target of $5.69, implying potential upside of 36.5% over the next 12 months. 13 analysts currently cover EVH, with a consensus rating of Buy - 77% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $3.0.

EVH operates in the Healthcare sector with a market capitalisation of $471M. The stock is up 7.2% year-to-date and is currently trading near the lower end of its 52-week range of $2.1 – $10.08.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for EVH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Buy → Buy 2026-06-12 Building track record
Citigroup - Reiterated
Buy → Buy 2026-05-15 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-05-12 Building track record
Needham - Reiterated
Buy → Buy 2026-05-07 20% win rate (5 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-02 14% win rate (7 calls)
Citigroup - Reiterated
Buy → Buy 2026-02-26 Building track record
UBS - Reiterated
Buy → Buy 2026-02-26 33% win rate (6 calls)
Truist Securities - Reiterated
Buy → Buy 2026-02-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
20/30
Consensus clarity
6/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →